Outlook Therapeutics to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
Outlook Therapeutics to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
ISELIN, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced it will present at the OIS Retina Innovation Showcase being held May 4, 2024 in Seattle, WA.
新澤西州艾瑟林，2024年4月29日（環球新聞專線）——Outlook Therapeutics, Inc.（納斯達克股票代碼：OTLK）是一家致力於在美國和歐盟首次批准用於治療視網膜疾病的貝伐珠單抗眼科製劑的生物製藥公司，今天宣佈將在2024年5月4日在華盛頓州西雅圖舉行的OIS視網膜創新展示會上亮相。
Details for the presentations are as follows:
演講的詳情如下：
Innovation Showcase: Company Presentation
Russell Trenary, President and Chief Executive Officer
Saturday, May 4, 2024 at 8:35 AM PT
創新展示：公司介紹
羅素·特雷納裏，總裁兼首席執行官
太平洋時間 2024 年 5 月 4 日星期六上午 8:35
For more information and to register for this event, please visit OIS Retina Innovation Summit.
欲了解更多信息並報名參加此次活動，請訪問OIS Retina創新峯會。
About Outlook Therapeutics, Inc.
關於 Outlook Therapeutic
Outlook Therapeutics is a biopharmaceutical company working to achieve FDA and European Commission approval for the launch of ONS-5010/LYTENAVA (bevacizumab-vikg or bevacizumab gamma) as the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA and/or EC approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, EU, United Kingdom, Europe, Japan, and other markets. As part of the Outlook Therapeutics' multi-year commercial planning process, Outlook Therapeutics and Cencora entered into a strategic commercialization agreement to expand the Outlook Therapeutics' reach for connecting to retina specialists and their patients. Cencora will provide third-party logistics (3PL) services and distribution, as well as pharmacovigilance services and other services in the United States.
Outlook Therapeutics是一家生物製藥公司，致力於獲得美國食品藥品管理局和歐盟委員會的批准，以推出ONS-5010/LYTENAVA（貝伐珠單抗-vikg或貝伐珠單抗伽瑪），這是首款獲批准的用於視網膜適應症（包括溼性AMD、DME和BRVO）的貝伐珠單抗眼科配方。如果 ONS-5010 眼用貝伐珠單抗獲得批准，Outlook Therapeutics預計將在美國、歐盟、英國、歐洲、日本和其他市場將其商業化，成爲美國食品藥品管理局和/或歐盟委員會批准的用於治療視網膜疾病的貝伐珠單抗眼科配方。作爲Outlook Therapeutics多年商業規劃過程的一部分，Outlook Therapeutics和Cencora簽訂了一項戰略商業化協議，以擴大Outlook Therapeutics與視網膜專家及其患者建立聯繫的覆蓋範圍。Cencora將在美國提供第三方物流（3PL）服務和配送，以及藥物警戒服務和其他服務。
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
OTLK@jtcir.com
投資者查詢：
珍妮·托馬斯
首席執行官
JTC Team, LLC
T: 833.475.8247
OTLK@jtcir.com
譯文內容由第三人軟體翻譯。